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journal homepage: www.ejves.comCorrespondenceWhy the United States Center for Medicare and Medicaid Services (CMS) Should
not Extend Reimbursement Indications for Carotid Artery Angioplasty/StentingA potential crisis looms in the United States of America – related
to the proposal for the US Center for Medicare and Medicaid
Services (CMS) to allow wider indications for government reim-
bursement for carotid angioplasty/stenting (CAS). We, the under-
signed, are writing to advise CMS to reject this proposal based
on overwhelming evidence that it would have serious negative
health and economic repercussions for the USA and any other
country that may follow such inappropriate action. The purpose
of this message is not to advise on existing CMS policy. Instead,
we wish to advise that current Medicare coverage for CAS should
not be extended to routine practice management of asymptomatic
carotid stenosis or symptomatic carotid stenosis where the patient
is considered at ‘low/average risk’ of complications from carotid
endarterectomy (CEA). We understand that, currently, CMS covers
the cost of CAS for the indications listed below (the National
Coverage Determination [NCD] for Percutaneous Transluminal
Angioplasty [PTA] March 5, 2010):
i. Concurrent with carotid stent placement when furnished
in accordance with the FDA-approved protocols governing
Category B Investigational Device Exemption (IDE) clinical
trials.
ii. Concurrent with the placement of an FDA-approved carotid
stent and an FDA-approved or -cleared embolic protection
device for an FDA-approved indication when furnished in
accordance with FDA-approved protocols governing post-
approval studies.
iii. Concurrent with the placement of an FDA-approved carotid
stent with an FDA-approved or –cleared embolic protection
device for the patients who are at high risk for carotid endar-
terectomy (CEA) and who also have symptomatic carotid
artery stenosis >70%.
iv. Patients who are at high risk for CEA and have symptomatic
carotid artery stenosis of 50%–70%, in accordance with the
Category B IDE clinical trials or in accordance with the NCD
on carotid artery stenting post-approval studies.
v. Patients who are at high risk for CEA and have asymptomatic
carotid artery stenosis>80%, in accordance with the Category
B IDE clinical trials regulation or in accordance with the NCD
on CAS post- approval studies.
According to the same NCD, patients at high risk for CEA are
deﬁned as having signiﬁcant comorbidities and/or anatomic risk
factors (i.e., recurrent stenosis and/or previous radical neck1078-5884/$ – see front matter  2011 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2011.12.006dissection), so that they would be considered poor candidates for
CEA. Signiﬁcant comorbid conditions include but are not limited to:
 Congestive heart failure (CHF) class III/IV;
 Left ventricular ejection fraction (LVEF) < 30%;
 Unstable angina;
 Contralateral carotid occlusion;
 Recent myocardial infarction (MI);
 Previous CEA with recurrent stenosis;
 Prior radiation treatment to the neck and
 Other conditions that were used to determine patients at high
risk for CEA in the prior carotid artery stenting trials and studies,
such as ARCHER, CABERNET, SAPPHIRE, BEACH, andMAVERIC II.’
Over the last 2–3 years the available evidence to direct current
best stroke-prevention management of carotid stenosis has been
reviewed by a number of leading academic clinicians. Current
routine practice management of carotid stenosis is based on
results of randomized trials of medical (non-invasive) intervention
alone versus additional CEA for patients with symptomatic1–3 or
asymptomatic4–7 carotid stenosis. In these trials patients were
randomized up to 30 years ago (1981–1994 and 1983–2003, respec-
tively). Overall, an average annual stroke prevention beneﬁt of
about 3.0% was measured for operated patients with moderate or
severe (70–99% NASCET equivalent) symptomatic8 carotid stenosis
and about 0.5–1% for operated patients with moderate or severe
(50–99% NASCET equivalent) asymptomatic7,9 carotid stenosis
compared to patients who received medical intervention alone.
More recently, trials of CAS versus CEA (without a medical
intervention-only-arm) were performed demonstrating that the
perioperative stroke risk is about twice as high with stenting
when comparedwith CEA (see below). These trials weremost likely
designed assuming medical intervention has not changed since the
randomized surgical trials, aiming to ﬁnd at least an equivalent CEA
stroke prevention beneﬁt. However, it is now clear that the stroke
prevention efﬁcacy of medical intervention has steadily and signif-
icantly improved over the last 30 years and continues to
improve,10–14 consistent with other observed falls in risk of
stroke,15–17 heart attack and sudden death.18 Currently used bench-
marks for a stroke prevention beneﬁt from CEA over medical inter-
vention (a 30-day procedural risk of stroke/death of 3% for
asymptomatic carotid stenosis19 or 6% for symptomatic carotid
stenosis)20 are outdated. Therefore, the demonstration of stroke
prevention equivalence between CAS and CEA using thesed by Elsevier Ltd. All rights reserved.
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to justify a current, routine practice indication for CAS.
The inappropriateness of the recent push for widening CMS
coverage for carotid stenting is particularly evident with respect to
ASYMPTOMATIC carotid stenosis because the randomized surgical
trial strokepreventionbeneﬁt fromCEAwas so small and conditional.
However, themost recent standardizedmeasurements of the average
annual rate of ipsilateral stroke among patients receiving medical
intervention alone approximate only 0.5%.11,21–23 This is about three
times lower than for randomized surgical trial CEA patients,5 about
ﬁve times lower than randomized surgical trial non-operated
patients,5 three times lower than CREST stented patients24and about
half the rate of CREST CEA patients.10,11,24 The push for routine prac-
tice stenting for asymptomatic carotid stenosis is based largely on
the recently published CREST results,24 and perhaps other clearly
ﬂawed randomized data,25,26 comparing CEA with CAS (without
a medical intervention-only-arm) and implications of ‘equivalence’
with CEA.27 As mentioned, such equivalence, even if supported by
the data, would not be sufﬁcient to justify a current, routine practice
indication for CAS for asymptomatic carotid stenosis.
However, to add insult to injury, an equivalent stroke prevention
beneﬁt between CAS and CEA has not been demonstrated. CAS in
CREST,24 large registries and population based studies28–30 has
beenassociatedwith aboutdouble theperi-procedural rateof stroke
or death compared to CEA. Further, in CREST, among asymptomatic
patients, the rate of peri-procedural stroke/death or later ipsilateral
stroke projected to four yearswas4.5% for 594patientswhohadCAS
and 2.7% for the 587 who had CEA (67% higher, P ¼ 0.07). This
outcome measure reached statistical signiﬁcance when symptom-
atic patients were added (6.4% vs. 4.7%, 36% higher, P ¼ 0.03). The
inclusion of higher risk symptomatic patients, and larger sample
sizes, allows easier detection of statistically signiﬁcant differences.
Supporters of routine CAS for asymptomatic carotid stenosis have
tried to use a higher incidence of peri-proceduralmyocardial infarc-
tion (including minor infarction) associated with CEA to justify
a higher stroke/death risk with CAS.31 However, this is invalid and
distracting because the aim of invasive carotid intervention is to
prevent stroke. Further, in CREST, at least, a larger proportion of
patients who suffered peri-proceduralmyocardial infarction associ-
ated with CAS (compared to CEA) died during follow-up.32 More
importantly, procedure associated myocardial damage would be
prevented entirely if unnecessary CEA and CAS interventions were
not performed in the ﬁrst place. In addition, it should also be noted
that CAS has higher procedural costs compared to CEA.33
The current situation regarding CEA and CAS for patients with
asymptomatic stenosis in the United States is unjustiﬁed and
outdated. Up to about 90–95% of these procedures are being per-
formed for asymptomatic carotid stenosis,29,34 exposing patients to
unnecessary risk and causingunjustiﬁedexpenditure of 1–2billion
US health care dollars each year10,12,35–38 at a time when health care
costs need to be justiﬁed.39 Despite no previous CMS coverage for
routine practice CAS for asymptomatic carotid stenosis, rates of CAS
procedures are increasing dramatically, especially among cardiolo-
gists.40,41 Extending the approved indications for CAS will open the
ﬂoodgates for widespread CAS and expose patients to unnecessary
risk and greatly increase unjustiﬁed health expenditure.33
Broadening the indications for CAS reimbursement for SYMP-
TOMATIC carotid stenosis is also inappropriate. The request for
such broadening of reimbursement will, once again, be based on
the CREST trial conclusions24 and the recently published American
Heart Association (AHA) Guideline (approved by 13 other organiza-
tions),27 which states that “CAS is an alternative to CEA for the treat-
ment of symptomatic carotid stenosis.”. Equivalence of the two
procedures is implied.42,43 Unfortunately, the actual CREST data,44
most other randomized trial data,45–47 meta-analyses48,49 andregistry data28–30 do not justify this presumed equivalence of CAS
and CEA for symptomatic carotid stenosis.50,51 In symptomatic
patients, CAS, overall, is associated with about double the 30-day,
120-day, 6-month and/or 4-year risk of stroke or death compared
to CEA. The excessive CAS procedural risk of stroke or death is partic-
ularly notable in patients over 70 years of age,52 yet not conﬁned to
the oldest age groups.44 CAS is also associated with a much higher
peri-procedural risk of brain-imaging detected ischemic lesions
than CEA53 and a higher incidence of carotid re-stenosis.54–56 No
studies have shown CAS is better than CEA in preventing stroke in
patients with symptomatic carotid stenosis and procedural costs
are signiﬁcantly higher with CAS.33 Thus, the extension of Medicare
reimbursement to routine treatment for ‘low’ and ‘standard’CEA risk
patients with symptomatic carotid stenosis is not currently justiﬁed.
Thus, in summary, at this time, the evidence does not support
broadening reimbursement for CAS to routine management of
patients with asymptomatic carotid stenosis or patients with symp-
tomatic carotid stenosis considered at ‘low or standard’ risk from
CEA. It is acknowledged that this situationmay change in the future.
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